Molecular test algorithms for digestive tumours

BJMO - volume 13, issue 1, february 2019

A. Hébrant PhD, Ir , A. Jouret-Mourin MD, PhD, G. Froyen PhD, J. Van der Meulen PhD, M. De Man MD, R. Salgado MD, PhD, M. van den Eynde , N. D’Haene MD, PhD, G. Martens MD, PhD, E. van Cutsem , H.A. Poirel MD, PhD, S. Tejpar MD, PhD, J.L. van Laethem MD, PhD, K. Geboes MD, PhD, P. Pauwels MD, PhD, F. Dedeurwaerdere MD, B. Maes MD, PhD, J. De Grève MD, PhD, J. Vanhuysse , P. Peeters MD, L. Vanacker MD, M. Gomez-Galdon , M. Chintinne MD, PhD, A. Hendlisz MD, PhD, G. de Hertogh , X. Sagaert MD, PhD, M. Peeters MD, PhD, P. Vannuffel , P. Lefesvre MD, PhD, J. Vermeij , M. Simoens , T. Van den Mooter MD, N. van Damme , M. Van den Bulcke PhD

The Belgian Commission of Personalized Medicine has been created to advise the federal government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests. Here, we propose the Belgian strategy for molecular testing in the digestive tumours within a scientific-based framework. For each tested biomarker, a clinical test level is attached, which is key to establish the relevance of the test and to define the reimbursement. For each digestive tumour type, the different molecular tests are represented as decision trees with its test utility, test level and a brief technical test description.

(BELG J MED ONCOL 2019;13(1):4–10)

Read more

Prognostic and predictive value of primary tumour location in metastatic colorectal cancer: will the side change our treatment?

BJMO - volume 12, issue 6, october 2018

V. de Weerdt , E. van Cutsem

Metastatic colorectal cancer is a heterogeneous disease. Tumours arising from different regions of the colon are clinically and molecularly distinct. The differing molecular characteristics translate into a differential clinical outcome with right-sided tumours displaying a worse prognosis compared to left-sided tumours. Besides the prognostic relevance of the primary tumour location, several retrospective analyses suggest that the primary tumour location may also be predictive of treatment benefit from targeted therapy with anti-EGFR and anti-VEGF directed agents in the first-line treatment of RAS wild-type metastatic colorectal cancer.

(BELG J MED ONCOL 2018;12(6):271–274)

Read more

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

BJMO - volume 8, issue 2, may 2014

R. A. Popescu , R. Schäfer , R. Califano , R. Eckert , R. Coleman , J.-Y. Douillard , A. Cervantes , P. G. Casali , C. Sessa , E. van Cutsem , E. de Vries , N. Pavlidis MD, PhD, K. Fumasoli , B. Wörmann , H. Samonigg , S. Cascinu , J. J. Cruz Hernández , A. J. Howard , F. Ciardiello , R. A. Stahel , M. Piccart

The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries. Medical oncology is a core member of the MDT and offers cancer patients a comprehensive and systemic approach to treatment and care, while ensuring evidence-based, safe and cost-effective use of cancer drugs and preserving the quality of life of cancer patients through the entire ‘cancer journey’. Medical oncologists are also engaged in clinical and translational research to promote innovation and new therapies and they contribute to cancer diagnosis, prevention and research, making a difference for patients in a dynamic, stimulating professional environment. Medical oncologists play an important role in shaping the future of healthcare through innovation and are also actively involved at the political level to ensure a maximum contribution of the profession to Society and to tackle future challenges. This position paper summarises the multifarious and vital contributions of medical oncology and medical oncologists to today’s and tomorrow’s professional cancer care.

Reprinted from Annals of Oncology 2014;25(1):9–15 with permission of Oxford University Press.

(BELG J MED ONCOL 2014;8(2):30–7)

Read more

Stratified Medicine: a call for action

BJMO - volume 7, issue 1, february 2013

A. Awada MD, PhD, L. Annemans , D. Broeckx , P. Pauwels MD, PhD, S. Simoens , S. Van Belle , E. van Cutsem , E. Van Hoof , J. De Grève MD, PhD

(BELG J MED ONCOL 2013;7:15–19)

Read more